TWI605055B - Phenoxaphosphine compounds - Google Patents
Phenoxaphosphine compounds Download PDFInfo
- Publication number
- TWI605055B TWI605055B TW102143829A TW102143829A TWI605055B TW I605055 B TWI605055 B TW I605055B TW 102143829 A TW102143829 A TW 102143829A TW 102143829 A TW102143829 A TW 102143829A TW I605055 B TWI605055 B TW I605055B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- group
- compound
- composition
- alkyl
- Prior art date
Links
- 150000005033 phenoxaphosphines Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 150000004982 aromatic amines Chemical class 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 25
- 239000004215 Carbon black (E152) Substances 0.000 description 20
- 229930195733 hydrocarbon Natural products 0.000 description 20
- 150000002430 hydrocarbons Chemical class 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- -1 Phosphine compound Chemical class 0.000 description 13
- 229960005181 morphine Drugs 0.000 description 12
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000004770 highest occupied molecular orbital Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 7
- 238000004768 lowest unoccupied molecular orbital Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 5
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000005525 hole transport Effects 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000000607 proton-decoupled 31P nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000000859 sublimation Methods 0.000 description 4
- 230000008022 sublimation Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003943 azolyl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003003 phosphines Chemical class 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000003775 Density Functional Theory Methods 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003115 supporting electrolyte Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SZNBBGIZLQDSGC-UHFFFAOYSA-N 4-(n-phenylanilino)phenol Chemical compound C1=CC(O)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SZNBBGIZLQDSGC-UHFFFAOYSA-N 0.000 description 1
- SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KENRRRNOXKWLGF-JXOJKODKSA-N ClC1[C@@H]2[C@@H]3C=C[C@@H]([C@H]4[C@@]3(C=3C(=C(C=CC13)O)O4)CCN2C)O Chemical class ClC1[C@@H]2[C@@H]3C=C[C@@H]([C@H]4[C@@]3(C=3C(=C(C=CC13)O)O4)CCN2C)O KENRRRNOXKWLGF-JXOJKODKSA-N 0.000 description 1
- 238000004057 DFT-B3LYP calculation Methods 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- YXLXNENXOJSQEI-UHFFFAOYSA-L Oxine-copper Chemical compound [Cu+2].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 YXLXNENXOJSQEI-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000245026 Scoliopus bigelovii Species 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000012467 brownies Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002484 cyclic voltammetry Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 150000001987 diarylethers Chemical class 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- JROGBPMEKVAPEH-GXGBFOEMSA-N emetine dihydrochloride Chemical compound Cl.Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC JROGBPMEKVAPEH-GXGBFOEMSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- XRRQZKOZJFDXON-UHFFFAOYSA-N nitric acid;silver Chemical compound [Ag].O[N+]([O-])=O XRRQZKOZJFDXON-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000012585 nuclear overhauser effect spectroscopy experiment Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical group [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/188—Metal complexes of other metals not provided for in one of the previous groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/50—Photovoltaic [PV] energy
- Y02E10/549—Organic PV cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Electroluminescent Light Sources (AREA)
Description
本發明係關於一種啡膦化合物。 The invention relates to a kind of brown Phosphine compound.
有機發光元件(OLED)係一種使用包含有機芳香族化合物的膜堆疊作為電致發光層的顯示裝置。此等化合物通常分類成電致發光材料及電荷傳輸材料。對此電致發光及電荷傳輸化合物所要求的數種性質包括在固態中之高螢光量子產率、高電子及電洞遷移率、在真空中蒸氣沈積期間之化學穩定性、及形成安定膜的能力。 An organic light emitting element (OLED) is a display device using a film stack containing an organic aromatic compound as an electroluminescent layer. Such compounds are generally classified into electroluminescent materials and charge transport materials. Several properties required for this electroluminescent and charge transporting compound include high fluorescence quantum yield in solid state, high electron and hole mobility, chemical stability during vapor deposition in vacuum, and formation of a stable film. ability.
OLED的共同問題包括快速老化/壽命短、不合意地高的操作電壓或不足的效率。發現出用於有機發光二極體(OLED)的電子傳輸層(ETL)及電洞傳輸層(HTL)之新型材料已經係改良元件性能及生命週期的目標。在HTL層的情況中,技藝技術的狀態係使用三芳基胺基底材料,其滿足許多現在的螢光及磷光OLED設計。在磷光OLED設計中,對藍色磷光OLED之大量製造來說,仍然存在有元件效率、生命週期及明亮度的問題。因此,對擁有相對於現在技術提高的性質之電洞傳輸層有需求。再者,對將電荷較 快傳輸至發射層且能夠具有長持續性及高效率元件的電洞傳輸材料有需求。這些需求及其它已經由下列發明滿足。 Common problems with OLEDs include rapid aging/short life, undesirably high operating voltages or insufficient efficiency. New materials for electron transport layers (ETL) and hole transport layers (HTL) for organic light-emitting diodes (OLEDs) have been found to improve component performance and life cycle goals. In the case of HTL layers, the state of the art technology uses a triarylamine base material that meets many of today's fluorescent and phosphorescent OLED designs. In the design of phosphorescent OLEDs, there are still problems of component efficiency, life cycle and brightness for the mass production of blue phosphorescent OLEDs. Therefore, there is a need for a hole transport layer that has an improved property relative to the current technology. Furthermore, the charge will be compared There is a need for a hole transport material that is fast to the emissive layer and that can have long lasting and high efficiency components. These needs and others have been met by the following inventions.
本發明提供一種包含至少一種選自於下列的化合物之組成物:A)
已經發現以中心啡膦核心為主的新型分子族群。此分子可透過下列調整:1)調整在磷中心處或在沿著啡膦核心的位置處之有機基團;及2)該磷中心的氧化狀態。這些衍生物的計算模型建議含有這些化合物的電荷傳輸層擁有較高的三重態,同時維持想要的HOMO及LUMO能階。再者,在R2、R3、R4、R5、R6、R7、R8及R9位置處的芳基胺取代讓穿越這些取代基所座落的苯環之HOMO軌域未定域化。結果,在該OLED元件中所形成的激子應該係良好侷限至該發射層,及允許改良元件明亮度、生命週期及效率。 Central morphine A new molecular group dominated by phosphine cores. This molecule can be adjusted by: 1) adjusting at the center of the phosphorus or along the brown An organic group at the position of the phosphine core; and 2) an oxidation state of the phosphorus center. The computational model of these derivatives suggests that the charge transport layer containing these compounds possesses a higher triplet state while maintaining the desired HOMO and LUMO energy levels. Furthermore, the arylamine substitution at the positions of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 leaves the HOMO orbital of the benzene ring traversing these substituents undetermined. Domainization. As a result, the excitons formed in the OLED element should be well confined to the emissive layer, and allow for improved component brightness, life cycle, and efficiency.
如上述討論,本發明提供一種組成物,其包含至少一種選自於下列的化合物:A)
本發明的組成物可包含二或更多個如描述於本文的具體實例之組合。 The compositions of the present invention may comprise two or more combinations as specific examples described herein.
如於本文中所使用,R1=R1、R2=R2、R3=R3等等。 As used herein, R1 = R 1, R2 = R 2, R3 = R 3 and the like.
在一個具體實例中,對式A來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係烴或經取代的烴;及對式B來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係烴或經取代的烴。 In one embodiment, for Formula A, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently a hydrocarbon or a substituted hydrocarbon; and for Formula B, R1 And R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently a hydrocarbon or a substituted hydrocarbon.
在一個具體實例中,對式A來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係氫、烷基、經取代的烷基、芳基、經取代的芳基、雜芳基或經取代的雜芳基;及 對式B來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係氫、烷基、經取代的烷基、芳基、經取代的芳基、雜芳基或經取代的雜芳基。 In one embodiment, for Formula A, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently hydrogen, alkyl, substituted alkyl, aryl, a substituted aryl, heteroaryl or substituted heteroaryl; For formula B, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, hetero Aryl or substituted heteroaryl.
在一個具體實例中,對式A來說,R2、R4、R5、R6、R7及R9每個係氫;及對式B來說,R2、R4、R5、R6、R7及R9每個係氫。 In one embodiment, for Formula A, R2, R4, R5, R6, R7, and R9 are each hydrogen; and for Formula B, R2, R4, R5, R6, R7, and R9 are each hydrogen. .
在一個具體實例中,對式A來說,R3及R8每個各自獨立地係烷基,及進一步係C1-C8烷基,及進一步係C1-C4烷基,及進一步係乙基或甲基;及對式B來說,R3及R8每個各自獨立地係烷基,及進一步係C1-C8烷基,及進一步係C1-C4烷基,及進一步係乙基或甲基。 In one embodiment, for Formula A, R3 and R8 are each independently alkyl, and further C1-C8 alkyl, and further C1-C4 alkyl, and further ethyl or methyl. And for the formula B, R3 and R8 are each independently an alkyl group, and further a C1-C8 alkyl group, and further a C1-C4 alkyl group, and further an ethyl group or a methyl group.
在一個具體實例中,對式A來說,R2、R3、R4、R5、R6、R7、R8及R9之至少一個係芳基胺;及對式B來說,R2、R3、R4、R5、R6、R7、R8及R9之至少一個係芳基胺。 In one embodiment, for Formula A, at least one of R2, R3, R4, R5, R6, R7, R8, and R9 is an arylamine; and for Formula B, R2, R3, R4, R5, At least one of R6, R7, R8 and R9 is an arylamine.
在一個具體實例中,對式A來說,R1包含至少六個碳原子;及對式B來說,R1包含至少六個碳原子。 In one embodiment, for Formula A, R1 comprises at least six carbon atoms; and for Formula B, R1 comprises at least six carbon atoms.
在一個具體實例中,該組成物包含式A之化合物及式B之化合物。 In one embodiment, the composition comprises a compound of formula A and a compound of formula B.
在一個具體實例中,該至少一種化合物係選自於下列:
在一個具體實例中,該至少一種化合物係選自於式A。 In one embodiment, the at least one compound is selected from Formula A.
在一個具體實例中,對式A來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係烴或經取代的烴。 In one embodiment, for Formula A, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently a hydrocarbon or a substituted hydrocarbon.
在一個具體實例中,對式A來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係氫、烷基、經取代的烷基、芳基、經取代的芳基、雜芳基或經取代的雜芳基。 In one embodiment, for Formula A, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently hydrogen, alkyl, substituted alkyl, aryl, Substituted aryl, heteroaryl or substituted heteroaryl.
在一個具體實例中,對式A來說,R2、R4、R5、R6、R7及R9每個係氫。 In one embodiment, for Formula A, R2, R4, R5, R6, R7, and R9 are each hydrogen.
在一個具體實例中,對式A來說,R3及R8每個各自獨立地係烷基,及進一步係C1-C8烷基,及進一步係C1-C4烷基,及進一步係乙基或甲基。 In one embodiment, for Formula A, R3 and R8 are each independently alkyl, and further C1-C8 alkyl, and further C1-C4 alkyl, and further ethyl or methyl. .
在一個具體實例中,對式A來說,R2、R3、R4、R5、R6、R7、R8及R9之至少一個係芳基胺。 In one embodiment, for Formula A, at least one of R2, R3, R4, R5, R6, R7, R8, and R9 is an arylamine.
在一個具體實例中,對式A來說,R1包含至少六個碳原子。 In one embodiment, for Formula A, R1 comprises at least six carbon atoms.
在一個具體實例中,對式A來說,每個R1進一步包含至少一個氧原子或至少一個氮原子。 In one embodiment, for Formula A, each R1 further comprises at least one oxygen atom or at least one nitrogen atom.
在一個具體實例中,對式A來說,R1進一步包含至少12個碳原子。 In one embodiment, for Formula A, R1 further comprises at least 12 carbon atoms.
在一個具體實例中,該至少一種化合物係選自於下列:
該式A之化合物可包含二或更多個如描述於本文的具體實例之組合。 The compound of formula A may comprise two or more combinations as specific examples described herein.
在一個具體實例中,該至少一種化合物係選自於式B。 In one embodiment, the at least one compound is selected from Formula B.
在一個具體實例中,對式B來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係烴或經取代的烴。 In one embodiment, for Formula B, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently a hydrocarbon or a substituted hydrocarbon.
在一個具體實例中,對式B來說,R1、R2、R3、R4、R5、R6、R7、R8及R9每個各自獨立地係氫、烷基、經取代的烷基、芳基、經取代的芳基、雜芳基或經取代的雜芳基。 In one embodiment, for Formula B, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently hydrogen, alkyl, substituted alkyl, aryl, Substituted aryl, heteroaryl or substituted heteroaryl.
在一個具體實例中,對式B來說,R2、R4、R5、R6、R7及R9每個係氫。 In one embodiment, for Formula B, R2, R4, R5, R6, R7, and R9 are each hydrogen.
在一個具體實例中,對式B來說,R3及R8每個各自獨立地係烷基,及進一步係C1-C8烷基,及進一步係 C1-C4烷基,及進一步係乙基或甲基。 In one embodiment, for Formula B, R3 and R8 are each independently alkyl, and further C1-C8 alkyl, and further C1-C4 alkyl, and further ethyl or methyl.
在一個具體實例中,對式B來說,R2、R3、R4、R5、R6、R7、R8及R9之至少一個係芳基胺。 In one embodiment, for Formula B, at least one of R2, R3, R4, R5, R6, R7, R8, and R9 is an arylamine.
在一個具體實例中,對式B來說,R1包含至少六個碳原子。 In one embodiment, for Formula B, R1 comprises at least six carbon atoms.
在一個具體實例中,對式B來說,每個R1進一步包含至少一個氧原子或至少一個氮原子。 In one embodiment, for Formula B, each R1 further comprises at least one oxygen atom or at least one nitrogen atom.
在一個具體實例中,對式B來說,R1進一步包含至少12個碳原子。 In one embodiment, for Formula B, R1 further comprises at least 12 carbon atoms.
在一個具體實例中,該至少一種化合物係選自於下列:,或其組合。 In one embodiment, the at least one compound is selected from the group consisting of: , Or a combination thereof.
該式B之化合物可包含二或更多個如描述於本文的具體實例之組合。 The compound of formula B may comprise two or more combinations as specific examples described herein.
在一個具體實例中,該至少一種化合物具有分子量大於或等於400克/莫耳,進一步大於或等於500克/莫耳。 In one embodiment, the at least one compound has a molecular weight greater than or equal to 400 grams per mole, and further greater than or equal to 500 grams per mole.
在一個具體實例中,該至少一種化合物具有分子量大於或等於600克/莫耳,進一步大於或等於700克/莫耳。 In one embodiment, the at least one compound has a molecular weight greater than or equal to 600 grams per mole, and further greater than or equal to 700 grams per mole.
在一個具體實例中,該至少一種化合物具有HOMO能階係-4.7電子伏特至-5.6電子伏特。 In one embodiment, the at least one compound has a HOMO energy system of from -4.7 electron volts to -5.6 electron volts.
在一個具體實例中,該至少一種化合物具有 LUMO能階係-1.0電子伏特至-3.0電子伏特。 In one embodiment, the at least one compound has The LUMO energy system is -1.0 eV to -3.0 eV.
在一個具體實例中,前述主張的任何之組成物,其中該至少一種化合物具有三重態能階係2.00電子伏特至4.00電子伏特。 In a specific embodiment, the composition of any of the preceding claims, wherein the at least one compound has a triplet energy system of 2.00 eV to 4.00 eV.
在一個具體實例中,該至少一種化合物具有昇華溫度大於或等於200℃。 In one embodiment, the at least one compound has a sublimation temperature greater than or equal to 200 °C.
在一個具體實例中,該至少一種化合物包含一或多個氘原子。 In one embodiment, the at least one compound comprises one or more deuterium atoms.
本發明的化合物可包含二或更多個如描述於本文的具體實例之組合。 The compounds of the invention may comprise two or more combinations as specific examples described herein.
在一個具體實例中,該組成物進一步包含金屬快得寧(quinolate)。在進一步具體實例中,該金屬快得寧係鋰快得寧。 In one embodiment, the composition further comprises a metal quinolate. In a further embodiment, the metal is faster than lithium.
在一個具體實例中,該組成物包含10至90重量百分比,進一步係10至70重量百分比的金屬快得寧,以該組成物的重量為基準。在進一步具體實例中,該組成物包含10至50重量百分比的金屬快得寧,以該組成物的重量為基準。在進一步具體實例中,該組成物包含20至50重量百分比的金屬快得寧,以該組成物的重量為基準。 In one embodiment, the composition comprises from 10 to 90 weight percent, further from 10 to 70 weight percent of the metal, based on the weight of the composition. In a further embodiment, the composition comprises from 10 to 50 weight percent of the metal, based on the weight of the composition. In a further embodiment, the composition comprises from 20 to 50 weight percent of the metal, based on the weight of the composition.
在一個具體實例中,該組成物包含10至90重量百分比,進一步10至70重量百分比的鋰快得寧,以該組成物的重量為基準。在進一步具體實例中,該組成物包含10至50重量百分比的鋰快得寧,以該組成物的重量為基準。在進一步具體實例中,該組成物包含20至50重量百分比的鋰 快得寧,以該組成物的重量為基準。 In one embodiment, the composition comprises from 10 to 90 weight percent, further from 10 to 70 weight percent of lithium, based on the weight of the composition. In a further embodiment, the composition comprises from 10 to 50 weight percent lithium fasting based on the weight of the composition. In a further embodiment, the composition comprises from 20 to 50 weight percent lithium Faster, based on the weight of the composition.
本發明的組成物可包含二或更多個如描述於本文的具體實例之組合。 The compositions of the present invention may comprise two or more combinations as specific examples described herein.
本發明亦提供一種膜,其包含至少一層從一或多個描述於本文的具體實例之發明的組成物所形成之層。 The invention also provides a film comprising at least one layer formed from one or more of the compositions of the invention described in the specific examples herein.
本發明亦提供一種電子裝置,其包含至少一層從一或多個描述於本文的具體實例之發明的組成物所形成之膜層。 The invention also provides an electronic device comprising at least one film layer formed from one or more of the compositions of the invention described in the specific examples herein.
本發明亦提供一種電子裝置,其包含至少一種從一或多個描述於本文的具體實例之發明的組成物所形成之構件。 The invention also provides an electronic device comprising at least one member formed from one or more of the compositions of the invention described in the specific examples herein.
本發明的組成物係在有機發光二極體(OLED)或相關的有機電子裝置,包括有機太陽能電池之應用中有用。更特別的是,本發明的組成物在OLED的各別層中找到應用,包括HIL(電洞注入層)、HTL(電洞傳輸層)、EML(發射層,包括宿主及摻雜物)、ETL(電子傳輸層)。 The compositions of the present invention are useful in applications in organic light emitting diodes (OLEDs) or related organic electronic devices, including organic solar cells. More particularly, the compositions of the present invention find applications in various layers of OLEDs, including HIL (hole injection layer), HTL (hole transport layer), EML (emitter layer, including host and dopant), ETL (Electronic Transport Layer).
本發明的膜可包含二或更多個如描述於本文的具體實例之組合。 The films of the present invention may comprise two or more combinations as specific examples described herein.
本發明的元件可包含二或更多個如描述於本文的具體實例之組合。 Elements of the invention may comprise two or more combinations as specific examples described herein.
本發明的組成物可包含二或更多個如描述於本文的具體實例之組合。 The compositions of the present invention may comprise two or more combinations as specific examples described herein.
該至少一種化合物可包含二或更多個如描述於本文的具體實例之組合。 The at least one compound may comprise two or more combinations as specific examples described herein.
式A之化合物可包含二或更多個如描述於本文的具體實例之組合。 A compound of formula A may comprise two or more combinations as specific examples described herein.
式B之化合物可包含二或更多個如描述於本文的具體實例之組合。 A compound of formula B may comprise two or more combinations as specific examples described herein.
本發明之電洞傳輸材料族群的合成典型需要製備經適當取代的10-氯啡膦。這些分子係與經適當取代的親核基反應以產生想要的啡膦物種。若必要時,可以H2O2氧化該啡膦衍生物以產生經取代的啡膦10-氧化物。該經取代的10-氯啡膦類之合成可遵循現存技藝,使用可商業購得的二芳基醚類、AlCl3及PCl3達成(Vedejs,E.;Marth,C.F.J.Am.Chem.Soc.1988,110,3948-3958)。為了產生擁有磷-C(芳基)交互作用的衍生物,該10-氯啡膦類係與芳基鋰試劑反應。在磷-O鍵聯的情況中,該10-氯啡膦類係於鹼存在下與經取代的酚反應,以產生想要的產物。該相應的啡膦10-氧化物係藉由這些產物與H2O2之反應合成。依啡膦10-氧化物的R取代而定,這些分子可進一步衍生以產生電洞傳輸分子。參見例如,下列反應圖解。 The synthesis of the population of hole transport materials of the present invention typically requires the preparation of appropriately substituted 10-chloromorphs. phosphine. These molecules react with appropriately substituted nucleophiles to produce the desired form Phosphine species. If necessary, H 2 O 2 can oxidize the film Phosphine derivatives to produce substituted brownies Phosphine 10-oxide. Substituted 10-chloromorphine The synthesis of phosphines can be accomplished following existing techniques using commercially available diaryl ethers, AlCl3 and PCl3 (Vedejs, E.; Marth, CFJAm. Chem. Soc. 1988, 110, 3948-3958). In order to produce a derivative having a phosphorus-C (aryl) interaction, the 10-chloromorph The phosphine system is reacted with an aryl lithium reagent. In the case of a phosphorus-O linkage, the 10-chloromorph The phosphines are reacted with a substituted phenol in the presence of a base to produce the desired product. The corresponding brown The phosphine 10-oxide is synthesized by the reaction of these products with H 2 O 2 . Immune Depending on the R substitution of the phosphine 10-oxide, these molecules can be further derivatized to produce a hole transporting molecule. See, for example, the following reaction scheme.
如於本文中所使用,用語”烴”指為僅包含碳及氫 原子(H及C;H;或C)的化學基團。如於本文中所使用,用語”烴”包括氫。 As used herein, the term "hydrocarbon" means only carbon and hydrogen. A chemical group of an atom (H and C; H; or C). As used herein, the term "hydrocarbon" includes hydrogen.
如於本文中所使用,用語”經取代的烴”指為具有一或多個氫各自獨立地經另一個包含至少一個雜原子的基團取代,及/或一或多個碳各自獨立地經另一個包含至少一個雜原子的基團取代之烴。 As used herein, the term "substituted hydrocarbon" is intended to mean that one or more hydrogens are each independently substituted with another group comprising at least one hetero atom, and/or one or more carbons are independently Another hydrocarbon substituted with a group containing at least one hetero atom.
如於本文中所使用,用語”芳基”代表衍生自芳香烴的有機基團。該芳基可係單環及/或稠環系統,其每個環可合適地包含4至7,較佳為5或6個環原子。亦包括二或更多個芳基經由單鍵結合的結構。特定實施例包括苯基、萘基、聯苯基、蒽基、茚基、茀基、菲基、三亞苯基、芘基、苝基、基、稠四苯基、丙二烯合茀基及其類似基團,但不限於此。該萘基可係1-萘基或2-萘基;該蒽基可係1-蒽基、2-蒽基或9-蒽基;及該茀基可係1-茀基、2-茀基、3-茀基、4-茀基及9-茀基之任何一種。 As used herein, the term "aryl" refers to an organic radical derived from an aromatic hydrocarbon. The aryl group may be a monocyclic and/or fused ring system, each ring suitably containing from 4 to 7, preferably 5 or 6 ring atoms. Also included is a structure in which two or more aryl groups are bonded via a single bond. Particular embodiments include phenyl, naphthyl, biphenyl, anthracenyl, fluorenyl, fluorenyl, phenanthryl, triphenylene, fluorenyl, fluorenyl, The group is a condensed tetraphenyl group, an allyl group, and the like, but is not limited thereto. The naphthyl group may be 1-naphthyl or 2-naphthyl; the fluorenyl group may be a 1-indenyl group, a 2-indenyl group or a 9-fluorenyl group; and the fluorenyl group may be a 1-indenyl group or a 2-indenyl group. Any of 3-mercapto, 4-indenyl and 9-fluorenyl.
如於本文中所使用,用語”雜芳基”指為包含至少一個選自於例如B、N、O、S、P(=O)、Si及P的雜原子,用於芳香族環狀骨架原子;及碳原子,用於剩餘的芳香族環狀骨架原子之芳基。該雜芳基可係5或6員單環雜芳基或多環雜芳基,其係與一或多個苯環稠合及可部分飽和。亦包括具有一或多個雜芳基經由單鍵鍵結的結構。該雜芳基可包括二價芳基,其雜原子經氧化或四級化以形成N-氧化物、四級鹽或其類似物。特定實施例包括但不限於單環雜芳基,諸如呋喃基、硫苯基、吡咯基、咪唑基、吡唑基、 噻唑基、噻二唑基、異噻唑基、異唑基、唑基、二唑基、三基、四基、三唑基、四唑基、呋呫基、吡啶基、吡基、嘧啶基、噠基;多環雜芳基,諸如苯并呋喃基、苯并噻吩基、異苯并呋喃基、苯并咪唑基、苯并噻唑基、苯并異噻唑基、苯并異唑基、苯并唑基、異吲哚基、吲哚基、茚唑基、苯并噻-二唑基、喹啉基、異喹啉基、喏啉基、喹唑啉基、喹喏啉基、咔唑基、啡啶基及苯并二呃基;及相應的N-氧化物(例如,吡啶基N-氧化物、喹啉基N-氧化物)及其四級鹽。 As used herein, the term "heteroaryl" refers to a heteroatom comprising at least one selected from, for example, B, N, O, S, P(=O), Si, and P, for use in an aromatic cyclic backbone. An atom; and a carbon atom for the aryl group of the remaining aromatic cyclic skeleton atom. The heteroaryl group can be a 5 or 6 membered monocyclic heteroaryl or polycyclic heteroaryl group fused to one or more benzene rings and partially saturated. Also included are structures having one or more heteroaryl groups bonded via a single bond. The heteroaryl group may include a divalent aryl group whose hetero atom is oxidized or quaternized to form an N-oxide, a quaternary salt or the like. Particular embodiments include, but are not limited to, monocyclic heteroaryls such as furyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, isomeric Azolyl, Azolyl, Diazolyl, three Base, four Base, triazolyl, tetrazolyl, furazolyl, pyridyl, pyridyl Base, pyrimidinyl, oxime Polycyclic heteroaryl such as benzofuranyl, benzothienyl, isobenzofuranyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, benziso Azolyl, benzo Azolyl, isodecyl, fluorenyl, oxazolyl, benzothia-oxadiazolyl, quinolyl, isoquinolyl, Porphyrin, quinazolinyl, quinoxalinyl, oxazolyl, phenanthryl and benzodiazepine a mercapto group; and a corresponding N-oxide (eg, pyridyl N-oxide, quinolinyl N-oxide) and a quaternary salt thereof.
取代基的實施例包括下列:氘、鹵素、含或不含鹵素取代基的(C1-C30)烷基、(C6-C30)芳基、含或不含(C6-C30)芳基取代基的(C3-C30)雜芳基、包含一或多個選自於例如B、N、O、S、P(=O)、Si及P的雜原子之5至7員雜環烷基、與一或多個芳香環稠合的5至7員雜環烷基、(C3-C30)環烷基、與一或多個芳香環稠合的(C6-C30)環烷基、三(C1-C30)烷基矽烷基、二(C1-C30)烷基(C6-C30)芳基矽烷基、三(C6-C30)芳基矽烷基、金剛烷基、(C7-C30)雙環烷基、(C2-C30)烯基、(C2-C30)炔基、氰基、咔唑基、NR2iR22、BR23R24、PR25R26、P(=O)R27R28[其中R2i至R28各自獨立地代表(C1-C30)烷基、(C6-C30)芳基或(C3-C30)雜芳基]、(C6-C30)ar(C1-C30)烷基、(C1-C30)烷基(C6-C30)芳基、(C1-C30)烷氧基、(C1-C30)烷硫基、(C6-C30)芳氧基、(C6-C30)芳硫基、(C1-C30)烷氧基羰基、(C1-C30)烷基羰基、(C6-C30)芳基羰基、(C6-C30)芳氧基羰基、(C1-C30)- 烷氧基羰基氧基、(C1-C30)烷基羰氧基、(C6-C30)芳基羰氧基、(C6-C30)-芳氧基羰基氧基、羧基、硝基及羥基;或毗連的取代基連結在一起以形成環。 Examples of substituents include the following: hydrazine, halogen, (C1-C30)alkyl with or without a halogen substituent, (C6-C30) aryl, with or without (C6-C30) aryl substituent (C3-C30)heteroaryl, 5- to 7-membered heterocycloalkyl containing one or more heteroatoms selected from, for example, B, N, O, S, P(=O), Si, and P, and Or a plurality of aromatic ring fused 5 to 7 membered heterocycloalkyl groups, (C3-C30)cycloalkyl group, (C6-C30) cycloalkyl group fused to one or more aromatic rings, and tris(C1-C30) Alkylalkyl, di(C1-C30)alkyl(C6-C30)aryldecyl,tri(C6-C30)aryldecyl,adamantyl,(C7-C30)bicycloalkyl, (C2 -C30)alkenyl, (C2-C30)alkynyl, cyano, oxazolyl, NR 2 iR 22 , BR 23 R 24 , PR 25 R 26 , P(=O)R 27 R 28 [where R 2 i To R 28 each independently represents (C1-C30)alkyl, (C6-C30)aryl or (C3-C30)heteroaryl], (C6-C30)ar(C1-C30)alkyl, (C1- C30) alkyl (C6-C30) aryl, (C1-C30) alkoxy, (C1-C30) alkylthio, (C6-C30) aryloxy, (C6-C30) arylthio, (C1 -C30) alkoxycarbonyl, (C1-C30)alkylcarbonyl, (C6-C30)arylcarbonyl, (C6-C30)aryloxycarbonyl, (C1-C30)-alkane Alkylcarbonyloxy, (C1-C30)alkylcarbonyloxy, (C6-C30)arylcarbonyloxy, (C6-C30)-aryloxycarbonyloxy, carboxy, nitro and hydroxy; or contiguous The substituents are joined together to form a ring.
全部的溶劑及試劑係以可商業購得的品質純(purum)、高純(puriss)或分析純(p.a.)獲得。乾溶劑係從室內純化/分配系統獲得(己烷、甲苯、四氫呋喃及二乙基醚),或從Sigma-Aldrich購買。包含水敏感化合物的全部實驗皆在經烤箱乾燥的玻璃器皿中、於氮大氣氛下或在氮氣箱中進行。反應係藉由分析型薄層層析法(TLC)在預塗佈的鋁板(VWR 60 F254)上監視,藉由UV光及/或過錳酸鉀染色顯像。快速層析法係在含有GRACERESOLV匣的ISCO COMBIFLASH系統上進行。 All solvents and reagents are obtained in commercially available quality purum, puriss or analytical grade (p.a.). Dry solvents were obtained from an in-house purification/dispensing system (hexane, toluene, tetrahydrofuran and diethyl ether) or purchased from Sigma-Aldrich. All experiments involving water-sensitive compounds were carried out in oven-dried glassware under a large nitrogen atmosphere or in a nitrogen box. The reaction was monitored by pre-coated aluminum plates (VWR 60 F254) by analytical thin layer chromatography (TLC) and stained by UV light and/or potassium permanganate. Flash chromatography was performed on an ISCO COMBIFLASH system containing GRACERESOLV(R).
1H-NMR-光譜(500MHz或400MHz)係在Varian VNMRS-400光譜儀上於30℃下獲得,除非其它方面有提到。化學偏移係參考下列之一:TMS在CHCl3中(δ=0.00)在CDCl3中。若需要的話,藉由COSY、HSQC或NOESY實驗之幫助進行波峰分配(peak assignment)。 1H-NMR-spectroscopy (500 MHz or 400 MHz) was obtained on a Varian VNMR S-400 spectrometer at 30 ° C unless otherwise mentioned. The chemical shift is referred to one of the following: TMS in CHCl3 (δ = 0.00) in CDCl3. If necessary, peak assignment is performed with the help of COSY, HSQC or NOESY experiments.
13C光譜(125MHz或100MHz)係在VNRMS-400光譜儀溶劑或標準訊號(0.0-TMS在CDCl3中)上獲得。 The 13C spectrum (125 MHz or 100 MHz) was obtained on a VNRMS-400 spectrometer solvent or standard signal (0.0-TMS in CDCl3).
如下進行例行性LC/MS研究。將五微升樣品液份注射在Agilent 1200SL二元梯度液相層析儀上,其中該液份如為”3毫克/毫升在THF中的溶液”,其中該層析儀係與 Agilent 6520 QT的四極飛行時間MS系統耦合,經由雙噴灑電灑(ESI)介面,以PI模式操作。使用下列分析條件:管柱:150x4.6毫米ID 3.5微米Zorbax SB-C8;管柱溫度:40℃;動相:75/25 A/B至15/85 A/B在40分鐘下;溶劑A=0.1v%蟻酸在水中;溶劑B=THF;流動1.0毫升/分鐘;UV偵測:210至600奈米的二極體陣列(提取波長250,280奈米);ESI條件:氣體溫度365℃;氣流--8毫升/分鐘;毛細管--3.5千伏;噴霧器--40psi;碎裂器(fragmentor)--145伏特。 A routine LC/MS study was performed as follows. Five microliters of the sample was injected onto an Agilent 1200SL binary gradient liquid chromatograph, where the fraction was "3 mg/ml in THF", where the chromatograph was The Agilent 6520 QT's quadrupole time-of-flight MS system is coupled in PI mode via a dual-spray electrospray (ESI) interface. The following analytical conditions were used: column: 150 x 4.6 mm ID 3.5 micron Zorbax SB-C8; column temperature: 40 ° C; mobile phase: 75/25 A/B to 15/85 A/B at 40 minutes; solvent A =0.1v% formic acid in water; solvent B = THF; flow 1.0 ml / min; UV detection: 210 to 600 nm diode array (extraction wavelength 250,280 nm); ESI conditions: gas temperature 365 ° C ; gas flow - 8 ml / min; capillary - 3.5 kV; nebulizer - 40 psi; fragmentor - 145 volts.
使用WaveNano恆電位器(Pine Research Instrumentation)進行循環伏安法測量。各別使用銀/硝酸銀(銀線浸入新鮮製備的5mM在無水乙腈中的硝酸銀溶液,含有0.1M TBAP作為支援電解質)、鉑線及鉑盤(直徑1.6毫米)作為參考、抗衡及工作電極。對大約5mM在DCM(無水)中的分析物溶液測量全部氧化掃描,其中該溶液含有1M TBAP作為支援電解質;對5mM在THF(無水,無抑制劑)中的溶液進行全部還原掃描,其中該溶液含有0.1M TBAP。典型來說,以20毫伏特/秒的掃視速率進行3循環(6段)。能階係藉由補償4.7伏特而修正,以轉換成真空能階。 Cyclic voltammetry measurements were performed using a WaveNano potentiostat (Pine Research Instrumentation). Silver/nitric acid silver (silver wire immersed in freshly prepared 5 mM silver nitrate solution in anhydrous acetonitrile containing 0.1 M TBAP as supporting electrolyte), platinum wire and platinum disk (1.6 mm diameter) were used as reference, counter and working electrodes. A total oxidation scan was measured on approximately 5 mM of the analyte solution in DCM (anhydrous), which contained 1 M TBAP as a supporting electrolyte; a 5 mM solution in THF (anhydrous, no inhibitor) was subjected to a total reduction scan, wherein the solution Contains 0.1M TBAP. Typically, 3 cycles (6 segments) are performed at a scan rate of 20 millivolts per second. The energy level is corrected by compensating for 4.7 volts to convert to a vacuum level.
DSC係使用2000儀器,以10℃/分鐘的掃描速率進行,及全部循環皆在氮大氣氛中。樣品(約7-10毫克)係從室溫掃描至300℃,冷卻至-60℃,及再加熱至300℃。在第二次加熱掃描時測量玻璃轉換溫度(Tg)。使用TA Universal Analysis軟體進行資料分析。Tg係使用”反曲中點”方法計算。 The DSC was performed using a 2000 instrument at a scan rate of 10 ° C/min, and all cycles were in a large nitrogen atmosphere. The sample (about 7-10 mg) was scanned from room temperature to 300 ° C, cooled to -60 ° C, and reheated to 300 ° C. The glass transition temperature (T g ) was measured during the second heating scan. Data analysis was performed using the TA Universal Analysis software. The T g is calculated using the "recurved midpoint" method.
全部計算係使用Gaussian 09程式 1 。計算係使用雜化密度泛函理論(DFT)方法、B3LYP 2 及6-31G*(5d)基礎設定 3 進行。該單重態計算係使用閉合殼層近似法,及三重態計算係使用開殼層近似法。全部值係引用電子伏特(eV)。HOMO及LUMO值係從單重基態的最佳化幾何形狀之軌域能量來測量。三重態係以在最佳化的三重態與最佳化的單重態之總能量間的差異來測量。 All calculations use the Gaussian 09 program 1 . The calculations were performed using a hybrid density functional theory (DFT) method, B3LYP 2 and 6-31G* (5d) basis setting 3 . The singlet state calculation uses a closed shell approximation, and the triplet calculation uses an open shell approximation. All values refer to electron volts (eV). The HOMO and LUMO values are measured from the orbital energy of the optimized geometry of the single ground state. The triplet state is measured as the difference between the optimized triplet state and the total energy of the optimized singlet state.
1.Gaussian 09,Revision A.02,Frisch,M.J.;Trucks,G.W.;Schlegel,H.B.;Scuseria,G.E.;Robb,M.A.;Cheeseman,J.R.;Scalmani,G.;Barone,V.;Mennucci,B.;Petersson,G.A.;Nakatsuji,H.;Caricato,M.;Li,X.;Hratchian,H.P.;Izmaylov,A.F.;Bloino,J.;Zheng,G.;Sonnenberg,J.L.;Hada,M.;Ehara,M.;Toyota,K.;Fukuda,R.;Hasegawa,J.;Ishida,M.;Nakajima,T.;Honda,Y.;Kitao,O.;Nakai,N.;Vreven,T.;Montgomery,Jr.,J.A.;Peralta,J.E.;Ogliaro,F.;Bearpark,M.;Heyd,J.J.;Brothers,E.;Kudin,K.N.;Staroverov,V.N.;Kobayashi,R.;Normand,J.;Raghavachari,K.;Rendell,A.;Burant,J.C.;Iyengar,S.S.;Tomasi,J.;Cossi,M.;Rega,N.;Millam,J.M.;Klene,M.;Knox,J.E.;Cross,J.B.;Bakken,V.;Adamo,C.;Jaramillo,J.;Gomperts,R.;Stratmann,R.E.;Yazyev,O.;Austin,A.J.;Cammi,R.;Pomelli,C.;Ochterski,J.W.;Martin, R.L.;Morokuma,K.;Zakrzewski,V.G.;Voth,G.A.;Salvador,P.;Dannenberg,J.J.;Dapprich,S.;Daniels,A.D.;Farkas,O.;Foresman,J.B.;Ortiz,J.V.;Cioslowski,J.;Fox,D.J.,Gaussian,Inc.,Wallingford CT,2009。 1. Gaussian 09, Revision A.02, Frisch, MJ; Trucks, GW; Schlegel, HB; Scuseria, GE; Robb, MA; Cheeseman, JR; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson , GA; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, HP; Izmaylov, AF; Bloino, J.; Zheng, G.; Sonnenberg, JL; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, N.; Vreven, T.; Montgomery, Jr., JA; Peralta, JE; Ogliaro, F.; Bearpark, M.; Heyd, JJ; Brothers, E.; Kudin, KN; Staroverov, VN; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.;Burant,JC;Iyengar,SS;Tomasi,J.;Cossi,M.;Rega,N.;Millam,JM;Klene,M.;Knox,JE;Cross,JB;Bakken,V.;Adamo, C.;Jaramillo,J.;Gomperts,R.;Stratmann,RE;Yazyev,O.;Austin,AJ;Cammi,R.;Pomelli,C.;Ochterski,JW;Martin, RL;Morokuma,K.;Zakrzewski , VG; Voth, GA; Salvador, P. Dannenberg, JJ; Dapprich, S;. Daniels, AD; Farkas, O;. Foresman, JB; Ortiz, JV; Cioslowski, J;. Fox, DJ, Gaussian, Inc., Wallingford CT, 2009.
2.(a)Becke,A.D. J. Chem. Phys. 1993,98,5648。(b)Lee,C.;Yang,W.;Parr,R.G. Phys. Rev B 1988,37,785。(c)Miehlich,B.;Savin,A.;Stoll,H.;Preuss,H. Chem. Phys. Lett. 1989,157,200。 2. (a) Becke, AD J. Chem. Phys. 1993, 98, 5648. (b) Lee, C.; Yang, W.; Parr, RG Phys. Rev B 1988 , 37, 785. (c) Miehlich, B.; Savin, A.; Stoll, H.; Preuss, H. Chem. Phys. Lett. 1989, 157,200.
3.(a)Ditehfield,R.;Hehre,W.J.;Pople,J.A. J. Chem. Phys. 1971,54,724。(b)Hehre,W.J.;Ditchfield,R.;Pople,J.A. J. Chem. Phys. 1972,56,2257。(c)Gordon,M.S. Chem. Phys. Lett. 1980,76,163。 3. (a) Ditehfield, R.; Hehre, WJ; Pople, JA J. Chem. Phys. 1971, 54, 724. (b) Hehre, WJ; Ditchfield, R.; Pople, JA J. Chem. Phys. 1972, 56, 2257. (c) Gordon, MS Chem. Phys. Lett. 1980, 76, 163.
在已冷卻至0℃的4-溴三苯基胺(5.00克,15.4毫莫耳)之二乙基醚溶液(100毫升)中,在15分鐘的時期內,逐滴加入1.6M nBuLi(10.6毫升,17.0毫莫耳)。在此溫度下攪拌該經冷卻的溶液一小時,然後冷卻至-78℃。在此溫度下,逐滴加入10-氯-2,8-二甲基-10H-啡膦(4.45克,17.0毫莫耳)的四氫呋喃溶液(20毫升),在此之後,允許該懸浮 液逐漸加熱至室溫。在攪拌過夜後,讓該懸浮液過濾過塞里塑料塞,及移除溶劑至乾燥。將甲苯(100毫升)加入至殘餘物,及攪拌該懸浮液5分鐘。再次,讓該懸浮液過濾過塞里塑料塞,及溶劑體積減低至30毫升,然後加入己烷類(30毫升)以析出白色固體,藉由過濾收集(質量=6.50克,89.3%)。 In a solution of 4-bromotriphenylamine (5.00 g, 15.4 mmol) in diethyl ether (100 ml) cooled to 0 ° C, 1.6 M nBuLi (10.6) was added dropwise over a period of 15 minutes. ML, 17.0 millimoles). The cooled solution was stirred at this temperature for one hour and then cooled to -78 °C. At this temperature, 10-chloro-2,8-dimethyl-10H-morphine was added dropwise A solution of phosphine (4.45 g, 17.0 mmol) in tetrahydrofuran (20 mL), after which the suspension was allowed to gradually warm to room temperature. After stirring overnight, the suspension was filtered through a plug of plastic stopper and the solvent was removed to dryness. Toluene (100 mL) was added to the residue, and the suspension was stirred for 5 min. Again, the suspension was filtered through a plug of celite, and the volume of the solvent was reduced to 30 ml, then hexanes (30 ml) was added to precipitate a white solid, which was collected by filtration (yield = 6.50 g, 89.3%).
1 H NMR(400MHz,CDCl 3 )δ 2.32(s,6H),6.87(d,J=8赫茲,2H),6.99-7.08(m,8H),7.11-7.17(m,4H),7.19-7.24(m,$H),7.29(d,J=8赫茲)。 1 H NMR (400 MHz, CDCl 3 ) δ 2.32 (s, 6H), 6.87 (d, J = 8 Hz, 2H), 6.99-7.08 (m, 8H), 7.11-7.17 (m, 4H), 7.19-7.24 (m, $H), 7.29 (d, J = 8 Hz).
13 C{ 1 H}NMR(CDCl 3 )δ 20.6,117.4,117.7,122.0(d,J=8赫茲),128.4,125.0,129.2,131.5,132.7,132.8,133.1(d,J=25赫茲),134.8(d,J=41赫茲),147.1,148.3,153.2。 13 C{ 1 H} NMR (CDCl 3 ) δ 20.6, 117.4, 117.7, 122.0 (d, J = 8 Hz), 128.4, 125.0, 129.2, 131.5, 132.7, 132.8, 133.1 (d, J = 25 Hz), 134.8 (d, J = 41 Hz), 147.1, 148.3, 153.2.
31 P{ 1 H}NMR(CDCl 3 )δ -52.9。 31 P{ 1 H} NMR (CDCl 3 ) δ -52.9.
Tg=61.3℃。HOMO:測量值-5.3伏特;LUMO:測量值-2.1伏特。 T g = 61.3 ° C. HOMO: measured value - 5.3 volts; LUMO: measured value - 2.1 volts.
在4-(2,8-二甲基-10H-啡膦-10-基)-N,N-二苯基苯胺(8.00克,17.0毫莫耳)的CH2Cl2(50毫升)溶液中,加入 30%H2O2水溶液(6毫升)。在室溫下攪拌該二相混合物過夜,接著加入5毫升水。分離出有機餾分,以MgSO4乾燥,及藉由旋轉蒸發移除溶劑。以沸騰的MeOH達成產物再結晶(質量=8.15克,98.5%)。Tg=89.5℃。 In 4-(2,8-dimethyl-10H-morphine Phosphino-10-yl) -N, N- diphenyl aniline (8.00 g, 17.0 mmol) in CH 2 Cl 2 (50 ml) was added 30% aqueous H 2 O 2 (6 mL). The biphasic mixture was stirred at room temperature overnight, followed by the addition of 5 ml of water. The organic fraction was separated, dried MgSO 4, and solvent was removed by rotary evaporation. The product was recrystallized from boiling MeOH (mass = 8.15 g, 98.5%). T g = 89.5 ° C.
1 H NMR(400MHz,CDCl 3 )δ 2.34(s,6H),6.96(d,J=4赫茲,2H),7.09-7.12(m,6H),7.20(dd,J=4,8赫茲,2H),7.25-7.29(m,4H),7.33-7.39(m,4H),7.58(d,J=12赫茲,2H)。 1 H NMR (400 MHz, CDCl 3 ) δ 2.34 (s, 6H), 6.96 (d, J = 4 Hz, 2H), 7.09-7.12 (m, 6H), 7.20 (dd, J = 4, 8 Hz, 2H ), 7.25-7.29 (m, 4H), 7.33 - 7.39 (m, 4H), 7.58 (d, J = 12 Hz, 2H).
13 C{ 1 H}NMR(CDCl 3 )δ 20.6,114.7,115.7,117.9(d,J=8赫茲),119.8(d,J=16赫茲),124.5,125.9,129.5,130.7,132.4(d,J=14赫茲),133.4(d,J=12赫茲),134.6,146.5,150.8,153.7。 13 C{ 1 H} NMR (CDCl 3 ) δ 20.6, 114.7, 115.7, 117.9 (d, J = 8 Hz), 119.8 (d, J = 16 Hz), 124.5, 125.9, 129.5, 130.7, 132.4 (d, J = 14 Hz), 133.4 (d, J = 12 Hz), 134.6, 146.5, 150.8, 153.7.
31 P{ 1 H}NMR(CDCl 3 )δ 1.1。 31 P{ 1 H} NMR (CDCl 3 ) δ 1.1.
Tg=89.5℃。HOMO:測量值-5.5伏特;LUMO:測量值-2.1伏特。在昇華後之純度(LC-MS):99.6% T g = 89.5 ° C. HOMO: measured value - 5.5 volts; LUMO: measured value - 2.1 volts. Purity after sublimation (LC-MS): 99.6%
在10-氯-2,8-二甲基-10H-啡膦(1.85克,7.05毫莫耳)的甲苯(50毫升)溶液中,加入過量NEt3(10毫升),接著4-(二苯基胺基)酚(1.84克,7.05毫莫耳)的甲苯(20毫升)溶 液。在加入期間,形成大量無色析出物,其在室溫下攪拌過夜。讓該懸浮液過濾過塞里塑料,及在真空中移除溶劑,以提供灰白色殘餘物,從Et2O/己烷類再結晶,以提供無色固體(3.32克,96.6%)。 In 10-chloro-2,8-dimethyl-10H-morphine Phosphine (1.85 g, 7.05 mmol) in toluene (50 mL) was added an excess of NEt 3 (10 mL) followed by 4- (diphenyl amino) phenol (1.84 g, 7.05 mmol) in toluene (20 ml) solution. During the addition, a large amount of colorless precipitate was formed which was stirred at room temperature overnight. Have suspension was filtered through Celite, and the solvent removed in vacuo to provide an off-white residue from Et 2 O / hexanes recrystallization, to provide a colorless solid (3.32 g, 96.6%).
1 H NMR(400MHz,CDCl 3 )δ 2.48(s,6H),6.33(d,J=4赫茲,2H),6.83(d,J=4赫茲,2H),7.00-7.06(m,6H),7.17(d,J=8赫茲,2H),7.24-7.37(m,4H),7.30(dd,J=4,8赫茲,2H),7.73(d,J=12赫茲,2H)。 1 H NMR (400MHz, CDCl 3 ) δ 2.48 (s, 6H), 6.33 (d, J = 4 Hz, 2H), 6.83 (d, J = 4 Hz, 2H), 7.00-7.06 (m, 6H), 7.17 (d, J = 8 Hz, 2H), 7.24 - 7.37 (m, 4H), 7.30 (dd, J = 4, 8 Hz, 2H), 7.73 (d, J = 12 Hz, 2H).
13 C{ 1 H}NMR(CDCl 3 )δ 20.6,117.6,118.2(d,J=20赫茲),121.8(d,J=8赫茲),122.0,123.1,126.1,129.0,132.5(d,J=20赫茲),134.0,135.5(d,J=40赫茲),142.8,147.6,151.0(d,J=8赫茲),152.2。 13 C{ 1 H} NMR (CDCl 3 ) δ 20.6, 117.6, 118.2 (d, J = 20 Hz), 121.8 (d, J = 8 Hz), 122.0, 123.1, 126.1, 129.0, 132.5 (d, J = 20 Hz), 134.0, 135.5 (d, J = 40 Hz), 142.8, 147.6, 151.0 (d, J = 8 Hz), 152.2.
31 P{ 1 H}NMR(CDCl 3 )δ 64.0。Tg=未觀察。 31 P{ 1 H} NMR (CDCl 3 ) δ 64.0. T g = not observed.
在4-((2,8-二甲基-10H-啡膦-10-基)氧基)-N,N-二苯基苯胺(3.50克,7.18毫莫耳)的CH2Cl2(50毫升)溶液中,加入30%H2O2水溶液(3毫升)。在室溫下,攪拌該二相混合物過夜,接著加入5毫升水。分離出有機餾分,以MgSO4 乾燥,及藉由旋轉蒸發移除溶劑。以沸騰MeOH達成產物再結晶(質量=3.52克,97.4%)。Tg=55.6℃。 In 4-((2,8-dimethyl-10H-morphine) Phosphino-10-yl) oxy) -N, N- diphenyl aniline (3.50 g, 7.18 mmol) in CH 2 Cl 2 (50 ml) was added 30% H 2 O 2 aqueous solution (3 ml ). The biphasic mixture was stirred overnight at room temperature, followed by the addition of 5 ml of water. The organic fraction was separated, dried MgSO 4, and solvent was removed by rotary evaporation. The product was recrystallized from boiling MeOH (yield = 3.52 g, 97.4%). T g = 55.6 ° C.
1 H NMR(400MHz,CDCl 3 )δ 2.43(s,6H),6.80(d,J=4赫茲,2H),6.94(d,J=4赫茲,2H),7.00-7.05(m,6H),7.21-7.28(m,4H),7.30(d,J=8赫茲,2H),7.45(dd,J=4,8赫茲,2H),7.75(d,J=12赫茲,2H)。 1 H NMR (400MHz, CDCl 3 ) δ 2.43 (s, 6H), 6.80 (d, J = 4 Hz, 2H), 6.94 (d, J = 4 Hz, 2H), 7.00-7.05 (m, 6H), 7.21-7.28 (m, 4H), 7.30 (d, J = 8 Hz, 2H), 7.45 (dd, J = 4, 8 Hz, 2H), 7.75 (d, J = 12 Hz, 2H).
13 C{ 1 H}NMR(CDCl 3 )δ 20.6,112.4,113.7,118.2(d,J=12赫茲),122.3(d,J=8赫茲),112.6,123.9,125.4,129.2,133.2(d,J=12赫茲),135.3,144.8,145.8(d,J=12赫茲),147.7,155.2。 13 C{ 1 H} NMR (CDCl 3 ) δ 20.6, 112.4, 113.7, 118.2 (d, J = 12 Hz), 122.3 (d, J = 8 Hz), 112.6, 123.9, 125.4, 129.2, 133.2 (d, J = 12 Hz), 135.3, 144.8, 145.8 (d, J = 12 Hz), 147.7, 155.2.
31 P{ 1 H}NMR(CDCl 3 )δ 0.5。 31 P{ 1 H} NMR (CDCl 3 ) δ 0.5.
Tg=55.6℃。HOMO:測量值-5.5伏特;LUMO:測量值-2.1伏特。在昇華後之純度(LC-MS):99.8%。 T g = 55.6 ° C. HOMO: measured value - 5.5 volts; LUMO: measured value - 2.1 volts. Purity after sublimation (LC-MS): 99.8%.
在250毫升圓底燒瓶中,於N2下,加入二苯胺(5.26克,31.1毫莫耳)、2,8-二溴-10-苯基10H-啡膦10-氧化物(3.50克,7.77毫莫耳)、三級丁醇鈉(1.79克,18.7毫莫耳)及100毫升甲苯。逐滴加入Pd(OAc)2(70毫克,0.31毫莫耳)及PtBu3(126毫克,0.62毫莫耳)的甲苯溶液,及將該混合物加熱至迴流過夜。在冷卻至室溫後,藉由旋轉蒸發移除 有機溶劑以產生暗色殘餘物。將該殘餘物溶解在200毫升CH2Cl2及100毫升鹽水中,及收集有機餾分。以2x100毫升CH2Cl2清洗水相,及結合有機餾分,及以MgSO4乾燥。過濾該懸浮液,及藉由旋轉蒸發移除有機溶劑。從MeOH再結晶該暗色殘餘物以提供白色結晶固體,其係藉由快速管柱層析法(EtOAc:己烷;1:1)純化,以提供N2,N2,N8,N8,10-五苯基-10H-啡膦-2,8-二胺,如為白色固體(3.65克,&5%)。 In a 250 ml round bottom flask, diphenylamine (5.26 g, 31.1 mmol), 2,8-dibromo-10-phenyl 10H-morphine were added under N 2 Phosphine 10-oxide (3.50 g, 7.77 mmol), tertiary sodium butoxide (1.79 g, 18.7 mmol) and 100 mL toluene. Was added dropwise Pd (OAc) 2 (70 mg, 0.31 mmol) and P t Bu 3 (126 mg, 0.62 mmol) in toluene, and the mixture was heated to reflux overnight. After cooling to room temperature, the organic solvent was removed by rotary evaporation to give a dark residue. The residue was dissolved in 200 mL of CH 2 Cl 2 and 100 mL brine and organic fractions were collected. To 2x100 mL CH 2 Cl 2 washed with water, and the organic fractions were combined and dried MgSO 4. The suspension was filtered and the organic solvent was removed by rotary evaporation. This was recrystallized from MeOH to provide a dark residue as a white crystalline solid lines by flash column chromatography (EtOAc in: hexanes; 1: 1) to afford N 2, N 2, N 8 , N 8, 10-pentaphenyl-10H-morphine Phosphine-2,8-diamine as white solid (3.65 g, & 5%).
1 H NMR(400MHz,CDCl 3 )δ 6.97-7.02(m,12H),7.17-7.24(m,10H),7.29-7.31(dd,J=4,8赫茲,2H),7.40(m,2H),7.45-7.51(m,5H)。 1 H NMR (400MHz, CDCl 3 ) δ 6.97-7.02 (m, 12H), 7.17-7.24 (m, 10H), 7.29-7.31 (dd, J = 4,8 Hz, 2H), 7.40 (m, 2H) , 7.45-7.51 (m, 5H).
13 C{ 1 H}NMR(CDCl 3 )δ 114.9,115.7,116.8,118.6(d,J=14赫茲),124.2,125.0,129.1,129.6,132.5(d,J=12赫茲),132.7(d,J=14赫茲),134.1,146.0,152.3(d,J=121赫茲),154.9。 13 C{ 1 H} NMR (CDCl 3 ) δ 114.9, 115.7, 116.8, 118.6 (d, J = 14 Hz), 124.2, 125.0, 129.1, 129.6, 132.5 (d, J = 12 Hz), 132.7 (d, J = 14 Hz), 134.1, 146.0, 152.3 (d, J = 121 Hz), 154.9.
31 P{ 1 H}NMR(CDCl 3 )δ 1.2。 31 P{ 1 H} NMR (CDCl 3 ) δ 1.2.
Tg=104℃。HOMO:測量值-5.3伏特;LUMO:測量值-2.1伏特。在昇華後之純度(LC-MS):99.7%。 T g = 104 ° C. HOMO: measured value - 5.3 volts; LUMO: measured value - 2.1 volts. Purity after sublimation (LC-MS): 99.7%.
這些化合物可使用在用於OLED元件的膜層中。 These compounds can be used in the film layer for OLED elements.
Claims (12)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261740925P | 2012-12-21 | 2012-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201427987A TW201427987A (en) | 2014-07-16 |
TWI605055B true TWI605055B (en) | 2017-11-11 |
Family
ID=50950047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102143829A TWI605055B (en) | 2012-12-21 | 2013-11-29 | Phenoxaphosphine compounds |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP6474957B2 (en) |
KR (1) | KR20140081699A (en) |
CN (1) | CN103880885A (en) |
TW (1) | TWI605055B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6651712B2 (en) * | 2015-05-15 | 2020-02-19 | コニカミノルタ株式会社 | Organic electroluminescent device, method for manufacturing the same, display device, lighting device, organic electroluminescent device material, and novel compound |
KR20180021809A (en) * | 2015-06-30 | 2018-03-05 | 다우 글로벌 테크놀로지스 엘엘씨 | Cyclic urea compounds for electronic devices |
JP6808319B2 (en) * | 2015-12-28 | 2021-01-06 | 大電株式会社 | Organic electron transport material and organic electroluminescent device using it |
KR102547685B1 (en) | 2016-02-22 | 2023-06-27 | 삼성디스플레이 주식회사 | Organic light emitting device |
KR20190141053A (en) | 2018-06-12 | 2019-12-23 | 삼성디스플레이 주식회사 | Heterocyclic compound and organic light emitting device comprising the same |
CN110205117A (en) * | 2019-06-11 | 2019-09-06 | 武汉华星光电半导体显示技术有限公司 | Phenyl phosphorus oxygen thermal activation delayed fluorescence material and its synthetic method, electroluminescent device |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3226984B2 (en) * | 1992-09-21 | 2001-11-12 | 第一工業製薬株式会社 | New reactive flame retardant for polyester resin |
DE10225283A1 (en) * | 2002-06-07 | 2003-12-18 | Celanese Chem Europe Gmbh | New cyclic phosphine compounds useful as catalyst components for organometallic reactions |
KR101202340B1 (en) * | 2005-01-21 | 2012-11-16 | 삼성디스플레이 주식회사 | Blue electroluminescent compound and organo-electroluminescent device employing the same |
DE102005023437A1 (en) * | 2005-05-20 | 2006-11-30 | Merck Patent Gmbh | Connections for organic electronic devices |
DE102005043163A1 (en) * | 2005-09-12 | 2007-03-15 | Merck Patent Gmbh | Connections for organic electronic devices |
ES2420755T3 (en) * | 2009-05-14 | 2013-08-26 | Dow Global Technologies Llc | Phosphine-palladium complexes for telomerization of butadiene |
KR20140013001A (en) * | 2011-03-03 | 2014-02-04 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | Novel compound, charge transport material, and organic device |
JP5724588B2 (en) * | 2011-04-28 | 2015-05-27 | コニカミノルタ株式会社 | ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE AND LIGHTING DEVICE |
JP5782836B2 (en) * | 2011-05-27 | 2015-09-24 | コニカミノルタ株式会社 | ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, LIGHTING DEVICE, AND COMPOUND |
CN102827409B (en) * | 2012-08-13 | 2014-07-30 | 华南理工大学 | Halogen-free flame-retardant organosilane cross-linked polyethylene, and preparation method and composition thereof |
-
2013
- 2013-11-29 TW TW102143829A patent/TWI605055B/en not_active IP Right Cessation
- 2013-12-18 KR KR1020130158136A patent/KR20140081699A/en unknown
- 2013-12-20 CN CN201310714058.8A patent/CN103880885A/en active Pending
- 2013-12-20 JP JP2013263133A patent/JP6474957B2/en not_active Expired - Fee Related
-
2018
- 2018-10-09 JP JP2018190829A patent/JP2019048812A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019048812A (en) | 2019-03-28 |
JP6474957B2 (en) | 2019-02-27 |
CN103880885A (en) | 2014-06-25 |
TW201427987A (en) | 2014-07-16 |
JP2014122218A (en) | 2014-07-03 |
KR20140081699A (en) | 2014-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI605055B (en) | Phenoxaphosphine compounds | |
US20130248830A1 (en) | Charge transport layers and films containing the same | |
US20160248020A1 (en) | Compositions containing fluorene substituted triazine derived compounds, and electronic devices containing the same | |
JP2019038810A (en) | Phenophosphazine compound | |
Yin et al. | Benzobisoxazole-based electron transporting materials with high T g and ambipolar property: high efficiency deep-red phosphorescent OLEDs | |
KR102185567B1 (en) | Quinoline-benzoxazole derived compounds for electronic films and devices | |
US10103334B2 (en) | Compositions with triarylamine derivatives and OLED device containing the same | |
EP3240856A1 (en) | Fluorene derivatives as light emitting elements for electroluminescent devices | |
KR20180013969A (en) | An electronic device comprising an organic composition and an organic layer comprising the composition | |
KR20190039765A (en) | Spiroacridine derivatives useful as OLEDs | |
US9966537B2 (en) | Compositions with 2,3-disubstituted indoles as charge transport materials, and display devices fabricated therefrom | |
US10294203B2 (en) | Organic compound and electronic device comprising an organic layer comprising the organic compound | |
JP2012140389A (en) | Benzothienobenzothiophene compound, and organic light-emitting device using the same | |
Umasankar et al. | Pyrene appended terpyridine derivatives as electrochemiluminescence material for OLEDs: Characterization of photo-physical, thermal and electrochemical properties | |
KR20160050891A (en) | Imidazole derivative and organic electroluminescent device including the same | |
JP2012051855A (en) | Organic compound and organic light-emitting device using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |